ArticleCellular and molecular bioengineering2025
Endocytic Pathways and Actin Remodeling Mediate Everolimus-Induced VE-Cadherin Disorganization and Barrier Dysfunction.
Article in Cellular and molecular bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MMP8 exacerbates sepsis-induced pulmonary vascular leakage by disruption of endothelial VE-cadherin through ERK signalling.Molecular biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: VE-cadherin is a key component of endothelial adherens junctions, and its disorganization contributes to vascular dysfunction. While rapamycin analogs like everolimus (EVL) are clinically linked to endothelial barrier dysfunction (EBD), the underlying molecular mechanisms remain poorly defined. This study investigates how EVL alters VE-cadherin organization, trafficking, cytoskeletal architecture, and barrier function in endothelial cells. Methods: Human umbilical vein endothelial cells (HUVECs) were treated with 500 nM EVL for 4 or 24 h. Junctional VE-cadherin organization was quantified using confocal microscopy and the Junction Analyzer Program. Cytoskeletal changes were assessed via F-actin anisotropy, and pharmacologic inhibitors (chlorpromazine, chloroquine, and brefeldin A) were used to block clathrin-mediated endocytosis, lysosomal degradation, and Golgi trafficking, respectively. Barrier function was evaluated using TEER and 4 kDa FITC-dextran transwell assays. Results: EVL reduced continuous VE-cadherin and increased punctate junctions in a time-dependent but partially reversible manner. Inhibiting endocytosis or lysosomal degradation preserved VE-cadherin continuity, while Golgi disruption blocked recovery. EVL also increased F-actin anisotropy, reflecting enhanced stress-fiber alignment within individual cells, but transiently uncoupled intracellular actin organization from coordinated cytoskeletal alignment across the monolayer. Functionally, EVL decreased TEER and increased dextran permeability by 2.24-2.63-fold, indicating significant barrier disruption. Conclusions: EVL compromises endothelial barrier integrity by promoting VE-cadherin internalization and lysosomal degradation, accompanied by cytoskeletal remodeling and a Golgi-dependent, partial restoration of junctional VE-cadherin. These findings highlight endocytic, degradative, and Golgi-mediated trafficking pathways as key modulators of EVL-induced endothelial barrier dysfunction and provide mechanistic insight into the vascular effects of rapalog-based mTOR inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.